Rising levels of HIV drug resistance

November 30, 2017
Credit: CC0 Public Domain

HIV drug resistance is approaching and exceeding 10% in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, led by researchers at UCL and the World Health Organization (WHO) and funded by the Bill & Melinda Gates Foundation and the WHO.

The study, published today in The Lancet Infectious Diseases, looked at data for people who were beginning , and found that - particularly to one of the main types of first-line , NNRTIs - is increasing and those who exhibited were more likely to have previously been exposed to , often during pregnancy.

"Treatments for HIV have improved immensely in recent years, and close to 21 million people worldwide are now being treated with antiretroviral therapy. Yet to end the AIDS epidemic as a public health threat, minimising drug resistance will be one part of the response. Our findings show the importance of improving how we monitor drug resistance, and suggest we should review which drugs are included in first-line therapies," said the study's lead author, Professor Ravindra Gupta (UCL Infection & Immunity).

The researchers pulled together 358 datasets, including data from 56,044 adults across 63 low- to middle-income countries who were beginning first-line therapy for HIV from 1996 and 2016. The research was conducted by a team of 33 authors on five continents.

Current WHO treatment guidelines for first-line therapy recommend non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with nucleoside reverse transcription inhibitors (NRTI). The research team focused on studies that included data on the presence of drug-resistant mutations in the virus, most commonly resistant to NNRTI drugs.

The research team found that, from 2001-2016, the odds of drug resistance in low- to middle-income countries across Sub-Saharan Africa, Latin America and Asia were increasing. In particular, the yearly incremental increase in NNRTI resistance was greatest in Eastern Africa (29% annual increase) and in Southern Africa (23% annual increase, with an absolute increase of 1.8 percentage points from 2015 to 2016) and was the smallest in Asia (11% annual increase).

The study did not focus on high-income countries, but other studies have found that levels of drug resistance to NNRTIs in high-income countries were either plateauing or declining.

The study authors found drug resistance to be highest in Southern Africa, where 11.1% of people beginning first-line therapy had a virus with NNRTI drug-resistant mutations, compared to 10.1% in Eastern Africa, 7.2% in Western/Central Africa, and 9.4% in Latin America.

The study team also found that people starting therapy who self-report previous use of antiretroviral drugs are more likely to carry resistant virus, and are at greater risk of virological failure - that is, the risk the virus won't be adequately kept under control by the HIV treatment.

Their data suggests that in some areas, 10-30% of people presenting for antiretroviral therapy have previously been exposed to antiretroviral drugs.

"Many people develop drug resistance after being treated by antiretroviral drugs if they stop taking their medication - often due to personal reasons, difficulty accessing treatment providers, or drug supply issues that are common in low income regions. When these individuals restart treatment at a later date, they are less likely to respond to therapy and may pass on the drug-resistant strains to other people," explained Professor Gupta.

If no action is taken, drug resistance to NNRTIs exceeding 10% in people starting therapy could result in 890,000 more AIDS deaths and 450,000 more infections in Sub-Saharan Africa alone before 2030, as most people whose antiretroviral is unsuccessful have a drug-resistant virus, according to prior research.

However, a way forward exists and is being proposed by the World Health Organization. In July 2017, WHO published a new HIV drug resistance report, based on drug resistance national surveys conducted in 11 countries in Africa, Asia and Latin America. The report's findings concurred with this broader meta-analysis' results and showed that in 6 of the 11 countries surveyed over 10% of people starting HIV treatment had drug resistant strains.

"If we are to combat HIV drug resistance, we must ensure countries can do a good job in monitoring and responding to it when needed," said co-author Dr Silvia Bertagnolio of the World Health Organization. "New WHO guidelines and a global action plan aim to help make this happen."

WHO's guidelines on pre-treatment HIV drug resistance recommend that countries switch to more robust first-line treatment when levels of resistance reach 10%. The five-year Global Action Plan calls on all countries and partners to join efforts to prevent, monitor and respond to HIV drug resistance and to protect the ongoing progress towards the Sustainable Development Goal of ending the AIDS epidemic by 2030.

Explore further: UN warns of growing resistance to AIDS drugs

More information: The Lancet Infectious Diseases (2017). DOI: 10.1016/S1473-3099(17)30702-8

Related Stories

UN warns of growing resistance to AIDS drugs

July 20, 2017
Countries must halt the rise of AIDS drug resistance to prevent a swell in new infections and deaths and spiralling treatment cost, the UN's health agency warned Thursday.

Scientists call for increased surveillance as study assessing HIV drug resistance shows rising rates in Africa

July 22, 2012
New research published online first in the Lancet suggests that drug-resistant HIV has been increasing in parts of Sub-Saharan Africa since the roll-out of antiretroviral therapy nearly a decade ago.

HIV drug resistance is threatening gains of treatment

October 27, 2017
(HealthDay)—Resistance to antiretroviral therapy (ART) is threatening the recent gains of treatment in the rate of new HIV infections, according to a perspective article published online Oct. 25 in the New England Journal ...

Computational modeling of drug resistance to guide treatment decisions for HIV patients

September 20, 2017
A bioinformatic examination of HIV mutations documented in clinics could help guide the selection of antiretroviral therapies.

HIV drug resistance creeps higher: WHO

July 18, 2012
Drug resistance to HIV medicines has been creeping higher in parts of Africa and Asia but is not steep enough to cause alarm, said a survey released by the World Health Organization on Wednesday.

HIV patients showing signs of multidrug resistance in Africa

November 30, 2016
Significant numbers of patients whose HIV strains developed resistance to older generation drugs are also resistant to modern drugs, finds a new study led by UCL and funded by Wellcome.

Recommended for you

Study suggests a way to stop HIV in its tracks

December 1, 2017
When HIV-1 infects an immune cell, the virus travels to the nucleus so quickly there's not enough time to set off the cell's alarm system.

Discovery puts the brakes on HIV's ability to infect

November 30, 2017
Viewed with a microscope, the virus faintly resembles a pineapple—the universal symbol of welcome. But HIV, the virus that causes AIDS, is anything but that. It has claimed the lives of more than 35 million people so far.

Rising levels of HIV drug resistance

November 30, 2017
HIV drug resistance is approaching and exceeding 10% in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, ...

Male circumcision and antiviral drugs appear to sharply reduce HIV infection rate

November 29, 2017
A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School ...

Combination HIV prevention reduces new infections by 42 percent in Ugandan district

November 29, 2017
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections ...

Research on HIV viral load urges updates to WHO therapy guidelines

November 24, 2017
A large cohort study in South Africa has revealed that that low-level viraemia (LLV) in HIV-positive patients who are receiving antiretroviral treatment (ART) is an important risk factor for treatment failure.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.